| sirolimus / Generic mfg. |
| Not yet recruiting | 3 | 140 | | | The Perron Institute for Neurological and Translational Science , National Health and Medical Research Council | Inclusion Body Myositis | | | | |
| Recruiting | 3 | 140 | | | The Perron Institute for Neurological and Translational Science , National Health and Medical Research Council | Inclusion Body Myositis | | | | |
2004-000935-27: A Randomized, Open-label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy. |
|
|
| Ongoing | 3 | 20 | Europe | Rapamune 1mg, Rapamune 2mg, Rapamune 5mg, Rapamune oral solution 1mg/ml, Rapamune 1mg coated tablets, Rapamune 2mg coated tablets, Rapamune 5mg coated tablets: MA pending (positive opinion for procedure number EMEA/H/C/273/X/21 adopted on 21st oct-04), Rapamune oral solution 1mg/ml, Rapamune 1mg coated tablets, Rapamune 2mg coated tablets, Rapamune 5mg coated tablets: MA pending (positive opinion for procedure number EMEA/H/C/273/X/21 adopted on 21st oct-04), Rapamune oral solution 1mg/ml | Wyeth Research Division of Wyeth Pharmaceuticals Inc.Clinical Research & Development Department | Liver allograft recipients under maintenance therapy | | | | |
2006-006577-25`ACTRN12615000820505: A prospective randomized study comparing rapamune and tacrolimus vs. cyclosporine and methotrexate as immune prophylaxis in allogeneic hematopoietic stem cell transplantation, using HLA-A, -B, -DRB1 identical related or unrelated donors. A Nordic multicenter study. |
|
|
| Ongoing | 3 | 200 | Europe | Rapamune, Prograf, Sandimmun Neoral, Methotrexate, Rapamune, Prograf, Sandimmun Neoral, Methotrexate, Rapamune, Prograf, Sandimmun Neoral, Methotrexate | Karolinska Institutet, Nordic Bone Marrow Transplant Group (NBMT), Federation University | Stress, Anxiety, Depression | | | | |
2011-000088-28: A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial |
|
|
| Ongoing | 3 | 300 | Europe | Sirolimus, Mycophenolatmofetil, Cyclosporine, EU/1/01/171/007, EU/1/01/171/001, EU/1/96/005/001, EU/1/96/005/004, EU/1/96/005/005, Coated tablet, Oral liquid, Capsule, Tablet, Powder for concentrate for solution for infusion, Capsule, soft, Oral suspension, Concentrate and solvent for concentrate for solution for infusion, Rapamune, CellCept, Sandimmun | Fred Hutchinson Cancer Research Center | Graft versus host disease, Graft versus host disease is a process where donor cells may react against cells of your body causing inflammation that can involve the skin, liver and gastrointestinal system., Not possible to specify | | | | |
NCT00679042: Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol |
|
|
| Active, not recruiting | 3 | 21 | US | Islets of Langerhans transplantation, Islets of Langerhan (Islets), Basiliximab (Simulect®), Tacrolimus (Prograf®), Sirolimus (Rapamune®), Etanercept(Enbrel®), Exenatide (Byetta®) | CellTrans Inc. | Type 1 Diabetes Mellitus | 07/17 | 06/26 | | |
REACH3, NCT03112603 / 2016-004432-38: A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation |
|
|
| Completed | 3 | 330 | Europe, Canada, Japan, US, RoW | Ruxolitinib, Jakafi, INCB018424, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib | Incyte Corporation | Graft-versus-host Disease (GVHD) | 05/20 | 12/22 | | |
|
|
| Active, not recruiting | 3 | 75 | Europe | Sirolimus, No other treatment | Radboud University Medical Center | Vascular Malformations | 09/21 | 03/23 | | |
NCT05643872: A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita |
|
|
| Recruiting | 3 | 45 | US | PTX-022 | Palvella Therapeutics, Inc. | Pachyonychia Congenita | 10/23 | 11/23 | | |
| Recruiting | 3 | 140 | US, RoW | Sirolimus, Rapamune, Placebo | University of Kansas Medical Center, The Perron Institute | Inclusion Body Myositis | 09/26 | 09/26 | | |
NCT04736589: Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway |
|
|
| Not yet recruiting | 3 | 270 | RoW | Inetetamab, Rapamycin, Pyrotinib, Chemotherapy | Peking Union Medical College | Breast Cancer | 02/24 | 02/27 | | |
| Recruiting | 3 | 250 | Europe | Sirolimus, Rapamycine | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Vascular Malformations | 04/25 | 04/30 | | |
MILED, NCT03150914: Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial |
|
|
| Recruiting | 3 | 60 | US | Sirolimus, Rapamycin | University of Cincinnati, National Heart, Lung, and Blood Institute (NHLBI), National Center for Advancing Translational Sciences (NCATS), The LAM Foundation | LAM, Lymphangioleiomyomatosis | 06/25 | 06/25 | | |
NCT03901001: Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza |
|
|
| Recruiting | 3 | 160 | RoW | sirolimus and oseltamivir, Oseltamivir | Chinese University of Hong Kong | Influenza | 10/25 | 12/25 | | |
RaRE-TS, NCT05534672: Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex |
|
|
| Recruiting | 3 | 200 | Europe | Rapamycin, Placebo | Katarzyna Kotulska | Tuberous Sclerosis Complex | 06/27 | 06/27 | | |
| Active, not recruiting | 3 | 825 | US | Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88 | Pancreatic Cancer Action Network | Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma | 06/27 | 06/27 | | |
NCT05549167: Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA) |
|
|
| Recruiting | 3 | 117 | RoW | Sirolimus | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Juvenile Nasopharyngeal Angiofibroma | 09/29 | 12/29 | | |
2020-003231-19: Comparison of the efficacy and safety of rapamycin versus vigabatrin in the prevention of Tuberous Sclerosis Complex symptoms in infants in the randomized clinical trial Porównanie skuteczności i bezpieczeństwa wigabatryny i rapamycyny w zapobieganiu objawom stwardnienia guzowatego u niemowląt w randomizowanym badaniu klinicznym |
|
|
| Not yet recruiting | 2/3 | 60 | Europe | Granules for oral solution in sachet, Oral solution, SABRIL 500 mg, granules for oral solution, RAPAMUNE 1 mg/ml oral solution | The Children's Memorial Health Institute, Medical Research Agency | Tuberous Sclerosis ComplexEpilepsyTumors associated with Tuberous Sclerosis Complex Stwardnienie guzowatePadaczkaGuzy narządowe związane ze stwardnieniem guzowatym, Tuberous Sclerosis ComplexEpilepsyTumors associated with Tuberous Sclerosis Complex Stwardnienie guzowatePadaczkaGuzy związane ze stwardnieniem guzowatym, Diseases [C] - Nervous System Diseases [C10] | | | | |
SCRRYST, NCT06341998: Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children |
|
|
| Completed | 2/3 | 32 | RoW | sirolimus combined with chemotherapy in the treatment of recurrent/refractory yolk sac tumor in children | Shandong First Medical University | Germ Cell Tumor, Yolk Sac Tumor | 01/24 | 02/24 | | |
NCT04324411: Sirolimus Combined With ATRA for the Treatment of Auto-Immune Anemia |
|
|
| Not yet recruiting | 2/3 | 50 | RoW | sirolimus and ATRA | Peking Union Medical College Hospital | Autoimmune Anemia | 04/22 | 12/22 | | |
NCT04598204: Efficacy and Safety of Rapamycin to Complex Vascular Anomalies in Pediatric Patients |
|
|
| Recruiting | 2/3 | 30 | RoW | Treatment with oral rapmycin | Zhujiang Hospital | Vascular Anomalies | 12/22 | 12/22 | | |
NCT03500848: Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation |
|
|
| Not yet recruiting | 2/3 | 130 | RoW | Tacrolimus, FK-506, Fujimycin, Prograf, Protopic, Advagraf, Tacrolimus (Tacrolimus elimination), Sirolimus, Rapamune, MMF and/or steroids, Mycophenolate mofetil | Southern Medical University, China, First Affiliated Hospital, Sun Yat-Sen University, Nanfang Hospital of Southern Medical University | Liver Transplantation | 05/23 | 05/23 | | |
NCT04892212: Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis |
|
|
| Not yet recruiting | 2/3 | 20 | NA | Sirolimus, Rapamycin | Peking Union Medical College Hospital, North China Pharmaceutical Group Corporation | Lupus Nephritis, Immunosuppression, Effect of Drug | 06/23 | 10/23 | | |
NCT04948203: Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis |
|
|
| Recruiting | 2/3 | 60 | US | Sirolimus, RAPAMUNE | University of Chicago | Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID | 12/25 | 12/25 | | |
NCT03008148: Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM |
|
|
| Recruiting | 2/3 | 288 | RoW | CCRT, Temozolomide, Chemotherapy, Siroquine, JP001 | Johnpro Biotech, Inc. | Glioblastoma | 04/25 | 04/25 | | |
NCT04047576: Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis |
|
|
| Recruiting | 2/3 | 60 | RoW | Sirolimus, Corticosteroid, Prednisone | Peking University International Hospital | Retroperitoneal Fibrosis | 12/25 | 12/26 | | |
ViRap, NCT04987463: Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants |
|
|
| Recruiting | 2/3 | 60 | Europe | Vigabatrin, Rapamycin, Placebo, Placebo in liquid, Placebo in granules | Katarzyna Kotulska | Tuberous Sclerosis Complex | 03/26 | 03/26 | | |
ChiCTR2200065107: Rapamycin combined with roxadustin for the treatment of acquired pure red cell aplasia- a prospective, single-arm, open-lable, multicenter study |
|
|
| Recruiting | 2/3 | 80 | | Rapamycin combined with roxadustin | Soochow hopes hematonosis hospital; Soochow hopes hematonosis hospital, Soochow hopes hematonosis hospital | pure red cell aplasia | | | | |
